Pay in 4 interest-free payments of $6.96 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Diabetes Technol Ther 23(7):512516
It contains the active ingredient semaglutide , which belongs to a class of drugs known as GLP-1 receptor agonists
Graphical Abstract Similar content being viewed by others Introduction Non-alcoholic fatty liver disease (NAFLD) is considered to be the hepatic manifestation of the metabolic syndrome, which is believed to affect approximately 25% of adults worldwide and more than half of individuals with type 2 diabetes mellitus [1]
Of those taking CagriSema, 89.7% achieved at least 5% weight loss
The approval of tirzepatide introduced a novel option for those needing additional interventions to control their diabetes and weight
